PUBLISHER: Grand View Research | PRODUCT CODE: 1842045
PUBLISHER: Grand View Research | PRODUCT CODE: 1842045
The global enzyme immunoassay market size was valued at USD 17.78 billion in 2024 and is projected to reach USD 24.77 billion by 2033, growing at a CAGR of 3.68% from 2025 to 2033. The industry growth can be attributed to the increasing demand for automation in diagnostic tests, increasing prevalence of chronic and infectious diseases, and growing awareness and use of diagnostic services.
Moreover, the growing geriatric population and increasing healthcare expenditure are also expected to drive the market growth in the coming years.According to the WHO, by the year 2050, the global population aged 60 years and above is projected to double, reaching 2.1 billion individuals. Additionally, the number of people aged 80 years or older is expected to triple from 2020 to 2050, reaching a total of 426 million.
Enzyme Immunoassay (EIA) tests are extensively used to diagnose various infectious diseases, such as HIV, hepatitis B and C, tuberculosis, and certain types of influenza. According to WHO, 630, 000 people died from HIV-related causes globally, and 39.0 million people were living with HIV at the end of 2022. Governments and health organizations across the world implement public health campaigns to encourage regular HIV testing as a key strategy in HIV prevention and control. Such initiatives increase the utilization of EIA tests and drive the market.
Technological advancements are one of the significant drivers for the enzyme immunoassay market in the field of diagnostics for infectious diseases such as HIV, hepatitis B and C, tuberculosis, and certain types of influenza. Innovations in EIA technologies have led to improvements in test sensitivity, specificity, and speed, enhancing their utility in clinical settings. For instance, the development of automated EIA systems has significantly reduced manual labor and error rates while also increasing throughput capabilities. Large-scale screening procedures are made possible by this automation, which is particularly advantageous in regions with high disease prevalence and during public health campaigns. Robotic liquid handling systems and integrated assay platforms are examples of automation technologies that improve sample throughput, decrease hands-on time, and streamline the EIA workflow. Labs can efficiently process a large number of samples and satisfy the rising demand for diagnostic testing thanks to high-throughput EIAs.
Global Enzyme Immunoassay Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global enzyme immunoassay market report based on product, application,specimen end use, and region: